Treatment strategies for protein-losing enteropathy in Fontan-palliated patients

Cardiol Young. 2020 May;30(5):698-709. doi: 10.1017/S1047951120000864. Epub 2020 May 4.

Abstract

Objective: Protein-losing enteropathy is an infrequent but severe condition occurring after Fontan procedure. The multifactorial pathogenesis remains unclear and no single proposed treatment strategy has proven universally successful. Therefore, we sought to describe different treatment strategies and their effect on clinical outcome and mortality.

Material and methods: We performed a retrospective observational study. From the total cohort of 439 Fontan patients treated in our institution during the study period 1986-2019, 30 patients (6.8%) with protein-losing enteropathy were identified. Perioperative, clinical, echocardiographic, laboratory, and invasive haemodynamic findings and treatment details were analysed.

Results: Median follow-up after disease onset was 13.1 years [interquartile range 10.6]. Twenty-five patients received surgical or interventional treatment for haemodynamic restrictions. Medical treatment, predominantly pulmonary vasodilator and/or systemic anti-inflammatory therapy with budesonide, was initiated in 28 patients. In 15 patients, a stable remission could be achieved by medical or surgical procedures (n = 3 each), by combined multimodal therapy (n = 8), or ultimately by cardiac transplantation (n = 1). Phrenic palsy, bradyarrhythmia, Fontan pathway stenosis, and absence of a fenestration were significantly associated with development of protein-losing enteropathy (p = 0.001-0.48). Ten patients (33.3%) died during follow-up; 5-year survival estimate was 96.1%. In unadjusted analysis, medical therapy with budesonide and pulmonary vasodilator therapy in combination was associated with improved survival.

Conclusions: Protein-losing enteropathy is a serious condition limiting survival after the Fontan procedure. Comprehensive assessment and individual treatment strategies are mandatory to achieve best possible outcome. Nevertheless, relapse is frequent and long-term mortality substantial. Cardiac transplantation should be considered early as treatment option.

Keywords: Fontan operation; Protein-losing enteropathy; late mortality; treatment strategies.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Budesonide / adverse effects
  • Budesonide / therapeutic use*
  • Child
  • Combined Modality Therapy
  • Disease Management
  • Female
  • Fontan Procedure / adverse effects*
  • Heart Transplantation
  • Hemodynamics
  • Humans
  • Male
  • Protein-Losing Enteropathies / etiology
  • Protein-Losing Enteropathies / physiopathology
  • Protein-Losing Enteropathies / therapy*
  • Remission Induction
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • Vasodilator Agents / therapeutic use*
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Vasodilator Agents
  • Budesonide